Summary. Improving the quality of life and health of pregnant women and their rational pharmacotherapy are the main objectives of WHO. Ukraine occupies 72 place in terms of motherhood in the world. We have analyzed and compared the national and international reports, guidelines on requirements for treatment and prevention of preterm birth. We analyzed the real world data of the frequency of drug prescriptions using ABC / VEN analysis based on medical records about drug prescriptions for pregnant women, diagnosed according to ICD-10 -O47.0. We found that the most common in A group were drugs for 7 INN (14.58 % of total allocations) and the essential drugs was only sodium chloride, which indicated that not enough rational use of funds of patients. We studied the evidence data about progesterone for effective treatment of PB. Therefore, that is important to optimize pharmaceutical care for pregnant women and rational use of medicines for effective pharmacotherapy of PB according to current health technologies.
and Ukraine. Also, we studied the real world data on prescribing of drugs for the pregnant with threatened PB, and determined a  nancial cost for therapy, using ABC/ VEN-analysis and the effectiveness rates according to evidence data for progestogens for PB treatment. We used content-analysis for recommendations, ABC/VEN analysis for drug prescriptions, systematic review of data.
Results and discussion. According to WHO Preterm Birth, de ned as birth before 37 weeks of gestation, is the single most important determinant of adverse infant outcomes, in terms of survival and quality of life.. There are sub-categories of preterm birth, based on gestational age: extremely preterm (less 28 weeks), very preterm (28-32 weeks), moderate to late preterm (32-37 weeks) [26, 27] . Globally, it is the leading cause of perinatal and neonatal mortality and morbidity.
WHO published the new "Recommendations on interventions to improve preterm birth outcomes" in 2015. This guideline was developed using standard operating procedures which can improve the chances of survival and health outcomes for preterm infants. The recommendations include the evidence-based health technologies provided to the mother -for example steroid injections before birth, antibiotics when her water breaks before the onset of labour, and magnesium sulfate to prevent future neurological impairment of the child. As well as interventions for the newborn baby -for example thermal care (e.g. kangaroo mother care when babies are stable) , safe oxygen use, other treatments, and the Cochrane systematic reviews were used primarily.
Фармакоекономіка

Pharmacoeconomics
Every year for nearly 15 million babies are born preterm (before 37 weeks), and this number is rising. Preterm birth complications are the leading cause of death among children under 5 years of age, responsible for nearly 1 million deaths due to complications of preterm birth in 2015. Globally, prematurity is the leading cause of death in children under 5 years. And in almost all countries with reliable data, preterm birth rates are increasing. Many survivors face a lifetime of disability, including learning disabilities and visual and hearing problems. Also 75 % of them could be saved with current, cost-effective health technologies.
Data indicated across 184 countries, the rate of preterm birth ranged from 5 % to 18 % of babies born. In low-income countries, 50 % of the babies born at or below 32 weeks (2 months early) die due to a lack of feasible, cost-effective health technologies, such as warmth, and basic care for infections and breathing dif culties. In high-income countries, almost all of these babies survive.
According to the data of British premature baby support charity Bliss, about one in eight babies, or 80000 a year, are born prematurely, of these, 17 000 need intensive care in UK. Among the children born very prematurely (22 to 27 weeks), they found that mortality rates among boys and girls were 5.3 and 9.7 times higher in early childhood. In late childhood boys were 7.0 times more likely to die than other children. The most surprising result was the high age in these boys and girls where increased mortality was registered [18] .
Premature infants have an increased risk of dying in late childhood compared with healthy babies,they are signi cantly less likely to have children themselves. Mothers who were premature are more likely to give birth early as well. Several conditions can lead to premature delivery, including multiple pregnancy, gestational diabetes, pre-eclampsia or a stressful events, but about 30 % of premature births happen for no apparent reasons [5, 18, 19, 21, 23] .
Since 2004 the International Working Group to study issues and prevention of PB, that is Preterm Birth International Collaborative (PREBIC) was established. In 2014 in Denmark the First European Congress «Spontaneous premature labor» and the second International symposium of PREBIC was held [19] .
In May 2012 report "Born too soon. The global action report on preterm birth" was published. The authors were 45 international experts from 11 countries with support of 50 organizations. This document consists of 6 sections, four of which are devoted to using of good safe health technologies during pregnancy [11] .
One We ccompared the requirements for treatment of preterm birth in these recommendations and protocols, the results are given in Table 1: Our task was to analyze 102 medical records of pregnant women which diagnosed with PB (ICD-10: -O47.0)/ These patients were hospitalized in the gynecology department of Lviv Regional Hospital in 2016, January-June. We founded that 62 pregnant women were the  rst-time birth, 40 were second-time, and the mean age was 27.3 years.
It was established that for PB treatment was prescribed 75 trade names of drugs, corresponding to 46 INN of drugs and 2 dietary supplements. Most frequently pregnant women were receiving these drugs top 10 in Figure 1 .
In total, 689 prescriptions were made that on average was 6.75 drugs per pregnant, which indicated polypharmacy.
Using the ABC analysis, we evaluated the design prescriptions of drugs, distributing drugs into three groups depending on their consumption. Was determined that the value of drugs, the average retail cost of packaging on September 2016. The analysisof PB schemes revealed that the group included 7 drugs from A group for the INN (14.58 % of total prescriptions), which are the most costly drugs. In the group C is 11 and includes 30 names on drugs INN, whose share of prescriptions was 22.9 % and 62.5 %, respectively (Table. 1 ).
The analysis showed that among the drugs of group A weree selected such subgroups LS: G03 -"Hormones of sexual glands and the preparations, used for the pathology of the sexual sphere", B05 -"Blood substitutes and perfusion solutions", A11 -"Vitamin", A03 -"Drugs used in functional gastrointestinal disorders", G02 -"Other gynecological medicines", N07-"Other drugs acting on the nervous system». The largest share are sub V05 -a 26 appointments with B05X B and 68 appointments of B05X A, as well as preparations subgroup G03 and A11 -89 appointments and 70 respectively.
The highest cost was in group of progestogen drugs, and that were 10 trade names, of which 5 were in dosage forms for vaginal use, two dosage forms were in injectable and oral forms. Prescriptions of drugs of national producers amounted to 20 % of all prescriptions.
Next task was to analyze the evidence based pharmacy data on the effectiveness of progestogens. Because these drugs are prescribed most often for private drug therapy according to the analysis of medical records lists. We searched the evidence data in PubMed. We founded the evidence of effectiveness for vaginal progesterone for use in women with singleton pregnancy and a short cervix [14, 17] . Internal use of 17α-hydroxyprogesterone kapronat appropriate for women with a singleton pregnancy in history were PP [8] . Effective pharmacotherapy for the presence of a pregnant woman bleeding in the  rst trimester [9] . Dydrogesterone has more advantages compared with vaginal progesterone in women who became pregnant via IVF [10] , and also reduces the risk of miscarriage in women with suspected potential. Article 2016 shows that the effectiveness of progesterone (30 mg) is for the prevention of severe preeclampsia pregnant women at high risk [14, 25] . Not recommended for primary prevention private use 17α-hydroxyprogesterone kapronat and vaginal progesterone forms in multiple pregnancies, and 17α-hydroxyprogesterone kapronat -women with multiple pregnancies with a short cervix.
[8] Also, supplementation of progesterone in the  rst 12 weeks of pregnancy is not an effective way to prevent recurrent miscarriages [18] . However, research on the effectiveness of the pregnant women are held, also studied the impact on perinatal mortality, as  nal conclusions are dif cult to make. For ef cient and effective use of funds held by us VEN-analysis of consumption of medicines. This analysis divides drugs into three categories depending on their importance for the treatment of certain diseases: V -vital, E -necessary, N -minor, the importance of taking such drugs is questionable. The distribution of drugs to the appropriate category we conducted using a formal approach; if the drug was in the State logbook drug release 8 [5] and the National List of Essential medicines [6] , then attributed to the drug group V. When the drug was only one of these lists, then -in group E, in the absence of drugs in these documents -group N (tabl.2).
It was established , that according to a retrospective analysis of medical records the drug costs at the lowest purchase prices were 75354.25 UAH, the cost per one patient was 740 UAH in average.
The VEN analysis showed that 12 drugs on INN were formed a Vital group, but the group of A / V entered only one drug , it's a sodium chloride. The largest number in the group C were 9 drugs, though some of them, such as magnesium sulfate, nifedipine, there are in these documents as a preparations for tocolytic therapy. The share of essential drugs is 43.8 % (21 drugs on INN, and the non-essential are 31.3 % (15 drugs on INN) .
The next step was to analyze a data regarding evidencebased pharmacy on drug as progestogens. This group is often prescribing for pharmacotherapy PB according to our analysis of medical records. We used the results of the latest evidence-based data that is presented in searching network PubMed. Evidence-based data about progesterone for vaginal application for women with singleton pregnancy and a short cervix are presented [2, 9] . Intravenous using of 17α-hydroxyprogesterone capronate is appropriate for women with a singleton pregnancy in PB history [1] . Effective implementation of pharmacotherapy for the presence of a pregnant woman bleeding in the  rst trimester [9] . Dydrogesterone has more advantages compared with vaginal progesterone in women who became pregnant via IVF [26] , and also reduces the risk of miscarriage in women with suspected potential. In 2016 was published the results that showed the effectiveness (30 mg) for the prevention of severe preeclampsia pregnant women at high risk [12, 17] . Now it not recommended for primary prevention use of 17α-hydroxyprogesterone capronate and vaginal progesterone forms in multiple pregnancies, and 17α-hydroxyprogesterone capronate for women with multiple pregnancies with a short cervix [8] Also, supplementation of progesterone in the  rst 12 weeks of pregnancy is not found an effective method of prevention of repeat abortions isn't known [18] However, research on the effectiveness of even being pregnant and also studied the impact on perinatal mortality, so definitive conclusions difficult to do. For effective use we made VEN analysis. It makes it possible to distribute the drugs into 3 categories depending on their importance for the treatment of this disease: V -vital, E -essential, N -non-essential, the importance of these drugs are questionable. The distribution of drugs to the appropriate category performed using a formal approach based on the presence of drugs at the same time in the State Formulary 8 edition [14] , the National List of Essential medicines [10] , while the drug belonged to the group V. When the drug was only one of the above document then was in the group E, in the absence of drug in these documents was in group N ( Table 3) .
The proportion of essential drugs was 43.75 % (21 drugs on INN), and the non-essentials were 31.25 % (15 drugs on INN), such as Probiz Femina and Yodofol belonged to the group C / N. So these prescriptions are need to correct for optimization of ef cacy and safety of PB. 3.Using ABC / VEN analysis showed that the group A included 7 drugs for the INN, the group B and C included 11 and 30 drugs, respectively.
4.Progestines have a good evidence data, but it need to determine the less expensive scheme/ drugs for the treatment and prevention of PB using pharmacoeconomic analysis results in Ukraine.
Фармакоекономіка Pharmacoeconomics женщину и свидетильствует о полипрагмазии. Установлено, что в группе А наиболее назначаемыми были препараты по 7 МНН (14,58 % от общего объема) и основным лекарственным средствам является по потреблению натрия хлорид, что свидетельствует о недостаточно рациональном использовании финансовых средств пациентов.
Установлено, что суммарно расходы на назначенные лекарства при ПР составили 5354,3 грн, а расходы на фармакотерапию 1 пациентки были в среднем 740,2 грн.
Нами проанализированы доказательные данные о назначении прогестерона для лечения ПР. Установлено, что наиболее эффективным в лечении ПР по данным доказательной фармации является прогестерон в лекарственной форме для вагинального приема для женщин с короткой шейкой матки, а дигистростерон -при применении вспомогательных репродуктивных технологий. Необходимым является оптимизация фармацевтической помощи беременным при ПР по данным доказательной фармации и назначения экономически эффективной фармакотерапии для рационализации расходов пациенток.
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